pyrvinium has been researched along with Astrocytoma, Grade IV in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bakhshinyan, D; Bhatia, M; Doble, BW; Garg, N; Hallett, R; Hassell, JA; Lach, B; Mahendram, S; Manoranjan, B; McFarlane, N; Murty, NK; Nolte, SM; Provias, JP; Qazi, MA; Reddy, K; Singh, M; Singh, SK; Subapanditha, M; Venugopal, C; Vijayakumar, T; Vora, P | 1 |
1 other study(ies) available for pyrvinium and Astrocytoma, Grade IV
Article | Year |
---|---|
Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Self Renewal; Disease Models, Animal; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Regulatory Networks; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Prognosis; Pyrvinium Compounds; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |